CN110312723A - Acp-196盐的晶型、其制备方法、药物组合物和用途 - Google Patents

Acp-196盐的晶型、其制备方法、药物组合物和用途 Download PDF

Info

Publication number
CN110312723A
CN110312723A CN201780086288.0A CN201780086288A CN110312723A CN 110312723 A CN110312723 A CN 110312723A CN 201780086288 A CN201780086288 A CN 201780086288A CN 110312723 A CN110312723 A CN 110312723A
Authority
CN
China
Prior art keywords
acp
crystal form
solvent
crystal
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780086288.0A
Other languages
English (en)
Other versions
CN110312723B (zh
Inventor
盛晓红
盛晓霞
朱涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOLIPHARMA LLC
Original Assignee
SOLIPHARMA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOLIPHARMA LLC filed Critical SOLIPHARMA LLC
Publication of CN110312723A publication Critical patent/CN110312723A/zh
Application granted granted Critical
Publication of CN110312723B publication Critical patent/CN110312723B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B17/00—Sulfur; Compounds thereof
    • C01B17/69—Sulfur trioxide; Sulfuric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及ACP‑196(Acalabrutinib)盐的晶型，与已知的ACP‑196固体形式相比，本发明盐的晶型在结晶度、溶解度、吸湿性等方面具有优势。本发明还涉及所述ACP‑196盐的晶型的制备方法，其药物组合物及其在制备用于治疗和/或预防布鲁顿酪氨酸激酶(BTK)介导的病症如自身免疫性疾病或病症、异种免疫性疾病或病症、癌症包括淋巴瘤以及炎性疾病或病症的方法中的用途。

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN201780086288.0A 2017-02-20 2017-02-20 Acp-196盐的晶型、其制备方法、药物组合物和用途 Active CN110312723B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/074087 WO2018148961A1 (zh) 2017-02-20 2017-02-20 Acp-196盐的晶型、其制备方法、药物组合物和用途

Publications (2)

Publication Number Publication Date
CN110312723A true CN110312723A (zh) 2019-10-08
CN110312723B CN110312723B (zh) 2022-02-11

Family

ID=63170501

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780086288.0A Active CN110312723B (zh) 2017-02-20 2017-02-20 Acp-196盐的晶型、其制备方法、药物组合物和用途

Country Status (3)

Country Link
US (1) US10899770B2 (zh)
CN (1) CN110312723B (zh)
WO (1) WO2018148961A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112028896A (zh) * 2020-10-14 2020-12-04 奥锐特药业(天津)有限公司 阿卡替尼的新晶型及其制备方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108137605B (zh) * 2016-10-05 2021-07-13 杭州领业医药科技有限公司 Acp-196的晶型及其制备方法和药物组合物
WO2018148961A1 (zh) 2017-02-20 2018-08-23 杭州领业医药科技有限公司 Acp-196盐的晶型、其制备方法、药物组合物和用途
US11130917B2 (en) * 2018-08-20 2021-09-28 China Petroleum & Chemical Corporation Modified Y-type molecular sieve, catalytic cracking catalyst comprising the same, their preparation and application thereof
US20220002302A1 (en) 2018-09-25 2022-01-06 Cipla Limited Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor
IL298872A (en) * 2020-06-19 2023-02-01 Acerta Pharma Bv Dosage forms of eclobrutinib maleate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106243113A (zh) * 2011-07-19 2016-12-21 默沙东有限责任公司 作为btk抑制剂的选择的咪唑并吡嗪类
WO2017002095A1 (en) * 2015-07-02 2017-01-05 Acerta Pharma B.V. Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
WO2018148961A1 (zh) 2017-02-20 2018-08-23 杭州领业医药科技有限公司 Acp-196盐的晶型、其制备方法、药物组合物和用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106243113A (zh) * 2011-07-19 2016-12-21 默沙东有限责任公司 作为btk抑制剂的选择的咪唑并吡嗪类
WO2017002095A1 (en) * 2015-07-02 2017-01-05 Acerta Pharma B.V. Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112028896A (zh) * 2020-10-14 2020-12-04 奥锐特药业(天津)有限公司 阿卡替尼的新晶型及其制备方法

Also Published As

Publication number Publication date
US10899770B2 (en) 2021-01-26
US20190375755A1 (en) 2019-12-12
WO2018148961A1 (zh) 2018-08-23
CN110312723B (zh) 2022-02-11

Similar Documents

Publication Publication Date Title
CN108137605A (zh) Acp-196的晶型及其制备方法和药物组合物
CN110312723A (zh) Acp-196盐的晶型、其制备方法、药物组合物和用途
US20220267299A1 (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
JP2018501317A (ja) 安定した、溶媒和物が含まれないアプレミラスト結晶形ｉｉ、及びその製造方法
CN108137516A (zh) 奥扎莫德的晶型、其制备方法及药物组合物
AU2015330554A1 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
CN117295735A (zh) Tolebrutinib晶型、无定型及其制备方法和用途
CA2590735C (en) Process for the preparation of 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl) ethoxy}-5-tetrahydropyran-4-yloxyquinazoline, their intermediates and crystalline salts thereof
KR102477065B1 (ko) 1-(3-tert-부틸-1-p-톨릴-1H-피라졸-5-일)-3-(5-플루오로-2-(1-(2-하이드록시에틸)-1H-인다졸-5-일옥시)벤질)우레아 하이드로클로라이드의 결정 형태
JP7295025B2 (ja) （ｓ）－［２－クロロ－４－フルオロ－５－（７－モルホリン－４－イルキナゾリン－４－イル）フェニル］－（６－メトキシ－ピリダジン－３－イル）メタノールの結晶性形態
KR20210102497A (ko) 피리디노일피페리딘 5-ht1f 작용제에 관한 조성물 및 방법
US7271269B2 (en) Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods
CN110234639A (zh) 替吡法尼的晶型及其制备方法及药物组合物
CN106496234B (zh) 结晶形态的***[4,5-d]嘧啶化合物及其制备方法和用途
WO2023280272A1 (zh) 伊沃替尼和其盐的晶型及其制备方法和用途
WO2022253261A1 (zh) Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途
CN105949183B (zh) 阿齐沙坦酯的晶型及其制备方法
CN107868059B (zh) 一种喹唑啉衍生物的盐、其制备方法及应用
EP4186908A1 (en) Jak inhibitor compound and use thereof
EP4114835A1 (en) Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine
WO2024028273A1 (en) Novel crystalline forms of (s)-7-oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2h-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide and co-crystal forms thereof
AU2020378025A1 (en) Crystal form of Aprocitentan, preparation method therefor and use thereof
WO2023137035A1 (en) Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
CN116041323A (zh) Sigma-1受体激动剂的酸式盐、其晶型及其制备方法和应用
CN114437079A (zh) 吡咯嘧啶五元氮杂环化合物的晶型

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant